Drug intelligence / Profile preview

LTM1201AD

Development stage: Unknown
Lead developer: Brigham and Women's Hospital
Modality: Small Molecules
Administration: Oral

Overview

LTM1201AD is an investigational medication being studied for the treatment of obstructive sleep apnea (OSA). It is administered as a capsule before bedtime and is being evaluated for its effects on OSA phenotype traits and OSA severity during sleep. The drug appears to target the activation of hypoglossal motor neurons (HMN) to address the reduction in upper airway dilator muscle activity that occurs at sleep onset in OSA patients.

Beyond the preview

Go deeper on LTM1201AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTM1201AD.

Explore the full profile